Suchen
Cyclerion Therapeutics Inc
CYCNZur Watchlist hinzufügen
3.440USD
-0.060-1.71%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
14.59MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cyclerion Therapeutics Inc Unternehmen
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Cyclerion Therapeutics Inc Informationen
BörsenkürzelCYCN
Name des UnternehmensCyclerion Therapeutics Inc
IPO-datumMar 18, 2019
CEOGraul (Regina M)
Anzahl der mitarbeiter1
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse301 Binney Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon16176217722
Websitehttps://www.cyclerion.com/
BörsenkürzelCYCN
IPO-datumMar 18, 2019
CEOGraul (Regina M)
Führungskräfte von Cyclerion Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
910.24K
+38.57%
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
910.24K
+38.57%
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Cyclerion Therapeutics Inc?
Die fünf größten Anteilseigner von Cyclerion Therapeutics Inc sind: Dr. Peter M. Hecht, Ph.D.
Wie viele Institutionen halten Anteile an Cyclerion Therapeutics Inc (CYCN)?
Mit Stand vom 2026Q1 halten 37 Institutionen Anteile an Cyclerion Therapeutics Inc, mit einem Gesamtmarktwert von etwa 318.08K, was 7.35% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -667233.00 gestiegen.